Search results for "lipid"

showing 10 items of 3879 documents

Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a dec…

2022

Objectives: The aim of this study was to assess the incidence of being overweight and metabolic syndrome (MS) among people living with HIV (PHIV) in three different cross-sectional studies conducted over three different periods: 2005, 2011 and 2015. Methods: This was a multi-centre, nationwide study. Data were collected in three studies from the CISAI group - SIMOne, HIV-HY and STOPSHIV - and included a total of 3014 PHIV. Logistic regression [odds ratio (OR), 95% confidence interval (CI)] was used to account for age and gender difference among three groups when comparing MS prevalence and being overweight; potential confounders were accounted for by including them in the regression equatio…

AdultMaledyslipidaemiaantiretroviral therapyHIV InfectionsOverweightLogistic regressionBody Mass IndexCohort StudiesPrevalencemedicineoverweightHumansPharmacology (medical)Metabolic Syndromebusiness.industryHealth PolicyIncidence (epidemiology)Body WeightHIVweight gainOdds ratioMiddle Agedmedicine.diseaseConfidence intervalHIV; antiretroviral therapy; dyslipidaemia; metabolic syndrome; overweight; weight gainCross-Sectional StudiesInfectious Diseasesweight gain.Metabolic syndromemedicine.symptombusinessWeight gainDemographyCohort studyHIV Medicine
researchProduct

Long term hemodialysis aggravates lipolytic activity reduction and very low density, low density lipoproteins composition in chronic renal failure pa…

2009

Abstract Background Dyslipidemia, particularly hypertriglyceridemia is common in uremia, and represents an independent risk factor for atherosclerosis. Methods To investigate the effects of hemodialysis (HD) duration on very low density lipoprotein (VLDL) and low density lipoprotein (LDL) compositions and lipopolytic activities, 20 patients on 5 to 7 years hemodialysis were followed-up during 9 years. Blood samples were drawn at T0 (beginning of the study), T1 (3 years after initiating study), T2 (6 years after initiating study) and T3 (9 years after initiating study). T0 was taken as reference. Results Triacylglycerols (TG) values were correlated with HD duration (r = 0.70, P Conclusion De…

AdultMalelcsh:Diseases of the circulatory (Cardiovascular) systemVery low-density lipoproteinmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentLipolysisBlood lipidsLipoproteins VLDLRisk Assessmentchemistry.chemical_compoundRenal DialysisRisk FactorsInternal medicinemedicineHumansInsulinLongitudinal StudiesTriglyceridesDyslipidemiasLipoprotein lipaseApolipoprotein C-IIICholesterolbusiness.industryHypertriglyceridemianutritional and metabolic diseasesLipaseMiddle Agedmedicine.diseaseAtherosclerosisLipoproteins LDLLipoprotein LipaseEndocrinologyCholesterolchemistrylcsh:RC666-701Low-density lipoproteinLinear ModelsKidney Failure Chroniclipids (amino acids peptides and proteins)Apolipoprotein C-IIFemaleHepatic lipaseHemodialysisCardiology and Cardiovascular MedicinebusinessBiomarkersResearch ArticleBMC cardiovascular disorders
researchProduct

Gender differences on oxidative stress markers and complement component C3 plasma values after an oral unsaturated fat load test

2020

Abstract Objective Post-prandial lipaemia (PL), oxidative stress (OS), and complement component C3 (C3) values are related to the atherosclerosis process. The post-prandial response of C3 after an oral fat load test (OFLT) using unsaturated fat is poorly addressed. The aim of this study was to analyze and compare the post-prandial response of OS markers and C3 values in men and women after an OFLT using unsaturated fat. Methods The study included a total of 22 healthy subjects with normal lipids and normal blood glucose (11 men and 11 pre-menopausal women). An oral unsaturated fat load test (OFLT: 50 g fat per m2 body surface) was performed using a commercial liquid preparation of long chai…

AdultMalemedicine.medical_specialty030209 endocrinology & metabolismmedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundSex Factors0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)TriglyceridesFasting stateGeneral Environmental Science030219 obstetrics & reproductive medicineGlutathione Disulfidebusiness.industryUnsaturated fatHealthy subjectsGeneral EngineeringComplement C3FastingGlutathioneMiddle AgedPostprandial PeriodGlutathioneLipidsFats UnsaturatedOxidized GlutathioneOxidative StressEndocrinologychemistryGeneral Earth and Planetary SciencesFemaleCardiology and Cardiovascular MedicineNormal blood glucosebusinessLong chainBiomarkersOxidative stressClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).

2019

Fabry's disease (FD) is an X-linked lysosomal storage disorder caused by the deficient activity of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A) leading to intracellular accumulation of globotriaosylceramide (Gb3). Patients with amenable mutations can be treated with migalastat, a recently approved oral pharmacologic chaperone to increase endogenous alpha-Gal A activity. We assessed safety along with cardiovascular, renal, and patient-reported outcomes and disease biomarkers in a prospective observational multicenter study after 12 months of migalastat treatment under real-world conditions. Fifty-nine (28 females) patients (34 (57.6%) pretreated with enzyme replacement therapy) w…

AdultMalemedicine.medical_specialty1-DeoxynojirimycinTime FactorsGlobotriaosylceramideRenal function030226 pharmacology & pharmacyGastroenterologyVentricular Function Left03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMigalastatGermanymedicineClinical endpointHumansPharmacology (medical)Genetic Predisposition to DiseaseProspective StudiesPharmacologySphingolipidsVentricular Remodelingbusiness.industryEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry's diseaseFabry diseaseBlood pressureTreatment Outcomechemistry030220 oncology & carcinogenesisalpha-GalactosidaseMutationFabry DiseaseFemaleGlycolipidsbusinessBiomarkersGlomerular Filtration RateClinical pharmacology and therapeutics
researchProduct

Characterization of hypoechoic focal hepatic lesions in patients with fatty liver: diagnostic performance and confidence of contrast-enhanced ultraso…

2007

The objective of this study was to assess the diagnostic performance of contrast-enhanced ultrasound (CEUS) to characterize hypoechoic focal hepatic lesions (HFHL) in fatty liver (FL). A study group of 105 patients with FL and 105 HFHLs (52 malignant and 53 benign) underwent CEUS after SonoVue administration. Two blinded readers independently reviewed baseline ultrasound (US) and CEUS scans and classified each lesion as malignant or benign on a five-point scale of confidence, and recorded whether further imaging work-up was needed. Sensitivity, specificity, areas under the receiver operating characteristic (ROC) curve (A (z)), and interobserver agreement were calculated. We observed that th…

AdultMalemedicine.medical_specialtyAdenomaSulfur HexafluorideContrast MediaSensitivity and SpecificityAdenoma Liver CellCholangiocarcinomaFocal Hepatic LesionsFatty LiverContrast-enhanced UltrasoundHumansMedicinecontrast-enhanced ultrasoundfatty liverfocal hepatic lesionsRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyPhospholipidsAgedUltrasonographyNeuroradiologyAged 80 and overObserver VariationHyperplasiamedicine.diagnostic_testReceiver operating characteristicbusiness.industryLiver NeoplasmsUltrasoundFatty liverCONTRAST-ENHANCED ULTRASOUNDFATTY LIVERFOCAL HEPATIC LESIONInterventional radiologyGeneral MedicineMiddle Agedmedicine.diseaseFatty LiverLiverROC CurveArea Under CurveFemaleRadiologyHemangiomabusinessContrast-enhanced ultrasoundEuropean Radiology
researchProduct

Effectiveness of cascade filtration plasmapheresis in two patients affected by familial hypercholesterolemia

1995

Hypercholesterolemia has been recognised as a primary risk factor for coronary heart disease. Reduction of plasma levels of total and LDL cholesterol has been shown to decrease coronary atherosclerosis. Plasmapheresis represents an useful non-pharmacological tool to treat severe hypercholesterolemias. We have evaluated the effectiveness of a system of plasmapheresis using a cascade filtration method in two young male subjects (aged 16 and 26 years) with homozygous familial hypercholesterolemia. Both showed severe coronary atherosclerosis as determined by angiography. Procedures were performed at intervals of 7 days in each case. We observed a mean reduction of plasma levels of total cholest…

AdultMalemedicine.medical_specialtyAdolescentApolipoprotein Bmedicine.medical_treatmentFamilial hypercholesterolemiaFibrinogenGastroenterologyHyperlipoproteinemia Type IIchemistry.chemical_compoundInternal medicinemedicineHumansHyperlipoproteinemia Type IIRisk factorCoronary atherosclerosisbiologybusiness.industryCholesterolCholesterol LDLPlasmapheresisHematologyGeneral Medicinemedicine.diseaseEndocrinologychemistrybiology.proteinlipids (amino acids peptides and proteins)PlasmapheresisbusinessFiltrationmedicine.drugJournal of Clinical Apheresis
researchProduct

Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-media…

2011

Dalcetrapib increases high-density lipoprotein cholesterol (HDL-C) levels through effects on cholesteryl ester transfer protein (CETP). As part of the dalcetrapib dal-HEART clinical trial programme, the efficacy and safety of dalcetrapib is assessed in coronary heart disease (CHD) patients in the dal-VESSEL study (ClinicalTrials.gov identifier: NCT00655538), the design and methods of which are presented here. RESEARCH DESIGN AND STUDY METHOD: Men and women with CHD or CHD risk equivalent, with HDL-C levels50  mg/dL were recruited for a 36-week, double-blinded, placebo-controlled trial. After a pre-randomisation phase of up to 8 weeks, patients received dalcetrapib 600  mg/day or placebo in …

AdultMalemedicine.medical_specialtyAdolescentBrachial ArteryDalcetrapibCoronary DiseaseAtherosclerosis CETP inhibition Endothelial function Flow-mediated dilatation ester transfer protein density-lipoprotein cholesterol off-target toxicity cardiovascular-disease dependent vasodilation coronary risk nitric-oxide torcetrapib atherosclerosis cetpModels BiologicalPlaceboschemistry.chemical_compoundYoung AdultDouble-Blind Methodmedicine.arteryInternal medicineCholesterylester transfer proteinmedicineHumansSulfhydryl CompoundsBrachial arteryLipoprotein cholesterolFlow mediated vasodilatationAgedRationalizationbiologybusiness.industryAnticholesteremic AgentsEstersGeneral MedicineCetp inhibitionMiddle AgedAmidesCoronary heart diseaseClinical trialVasodilationTreatment OutcomechemistryRegional Blood FlowResearch DesignCardiologybiology.proteinlipids (amino acids peptides and proteins)FemaleEndothelium VascularbusinessAlgorithms
researchProduct

Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level

2014

Patients with diabetes caused by single-gene mutations generally exhibit an altered course of diabetes. Those with mutations of the glucokinase gene (GCK-MODY) show good metabolic control and low risk of cardiovascular complications despite paradoxically lowered high-density lipoprotein (HDL) cholesterol levels. In order to investigate the matter, we analyzed the composition of low-density lipoprotein (LDL) and HDL subpopulations in such individuals. The LipoPrint(©) system (Quantimetrix, USA) based on non-denaturing, linear polyacrylamide gel electrophoresis was used to separate and measure LDL and HDL subclasses in fresh-frozen serum samples from patients with mutations of glucokinase or …

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismBiologyLipid subpopulationsYoung Adultchemistry.chemical_compoundEndocrinologyMonogenic diabetesInternal medicineDiabetes mellitusGlucokinasemedicineInternal MedicineHumansHepatocyte Nuclear Factor 1-alphaChildType 1 diabetesmedicine.diagnostic_testCholesterolGlucokinaseCholesterol HDLCase-control studynutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaseLipoproteins LDLDiabetes Mellitus Type 1EndocrinologychemistryCase-Control StudiesMetabolic control analysisMODYOriginal ArticleFemalelipids (amino acids peptides and proteins)Lipoproteins HDLLipid profileLipoproteinActa Diabetologica
researchProduct

Elevated concentration of oxidized LDL together with poor cardiorespiratory and abdominal muscle fitness predicts metabolic syndrome in young men

2013

Metabolic syndrome (MetS) is associated with increased oxidized LDL (ox-LDL), systemic inflammation, and poor cardiorespiratory fitness. We examined affiliations of these factors and the effect of muscular fitness on MetS in young healthy men.Physical fitness, ox-LDL, tumor necrosis factor α (TNFα), interleukin-6 (IL-6) and serum lipids were measured in a nationally representative sample of Finnish young men with and without MetS. Participants (mean age 25.1years) performed tests of maximal oxygen uptake (VO₂max) and muscle fitness, and were divided into MetS (n=54, IDF 2007 criteria) and non-MetS (n=790). Age, smoking and leisure-time physical activity were used as covariates (ANCOVA).The …

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismPhysical fitnessBlood lipidsBiologyta3111Young AdultGrip strengthOxygen ConsumptionEndocrinologyPredictive Value of TestsRisk FactorsInternal medicinemedicineHumansYoung adultta315FinlandAbdominal MusclesMetabolic SyndromeInterleukin-6Tumor Necrosis Factor-alphabusiness.industryMyocardiumVO2 maxHeartCardiorespiratory fitnessMiddle Agedmedicine.diseaseRespiratory MusclesLipoproteins LDLCross-Sectional StudiesEndocrinologyPhysical FitnessMetabolic syndromebusinessBody mass indexMetabolism
researchProduct

Lipid subclasses profiles and oxidative stress in aggressive periodontitis before and after treatment

2015

Background and Objective: Associations between dyslipidaemia, oxidative stress and periodontitis have emerged in recent years. However, there is a lack of studies investigating these associations in aggressive periodontitis (AgP) cases. The aim of this study was to investigate the lipid and oxidative stress profiles in patients with AgP, and to relate them to clinical variables and interleukin (IL)-6 genetic variants. Material and Methods: Twelve non-smoking Caucasian patients with AgP selected based on their IL6 haplotypes underwent periodontal non-surgical and surgical treatment. Peripheral blood samples taken at baseline and at six different time-points after treatment were processed to …

AdultMalemedicine.medical_specialtyAdolescentEuropean Continental Ancestry GroupLongitudinal Studiemedicine.disease_causeWhite Peoplechemistry.chemical_compoundYoung AdultGeneticInternal medicinemedicineHaplotypeAggressive periodontitisHumansLongitudinal StudiesPeriodontitismedicine.diagnostic_testCholesterolbusiness.industryInterleukin-6PeriodontitiOxidative Stress.BiomarkerLipidmedicine.diseaseLipidsAggressive PeriodontitiOxidative StressEndocrinologyTreatment OutcomechemistryAggressive PeriodontitisHaplotypesPeriodonticsOxidative strelipids (amino acids peptides and proteins)FemaleMetabolic syndromebusinessLipid profileDyslipidemiaOxidative stressBiomarkersLipoproteinHuman
researchProduct